CoolMPS: evaluation of antibody labeling based massively parallel non-coding RNA sequencing by Li, Yongping et al.
Published online 8 December 2020 Nucleic Acids Research, 2021, Vol. 49, No. 2 e10
doi: 10.1093/nar/gkaa1122
CoolMPS: evaluation of antibody labeling based
massively parallel non-coding RNA sequencing
Yongping Li1,2,†, Tobias Fehlmann 1,†, Adam Borcherding3, Snezana Drmanac3,
Sophie Liu3, Laura Groeger4, Chongjun Xu2,3,5,6, Matthew Callow3, Christian Villarosa3,
Alexander Jorjorian3, Fabian Kern 1, Nadja Grammes1, Eckart Meese4, Hui Jiang2,
Radoje Drmanac2,3,5,6, Nicole Ludwig4,† and Andreas Keller 1,7,*,†
1Chair for Clinical Bioinformatics, Saarland University, 66123 Saarbrücken, Germany, 2MGI, BGI-Shenzhen,
Shenzhen 518083, China, 3Complete Genomics Incorporated, San Jose, CA 95134, USA, 4Department of Human
Genetics, Saarland University, 66421 Homburg, Germany, 5BGI-Shenzhen, Shenzhen 518083, China, 6China
National GeneBank, BGI-Shenzhen, Shenzhen 518120, China and 7Department of Neurology and Neurological
Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA
Received May 15, 2020; Revised October 02, 2020; Editorial Decision November 02, 2020; Accepted November 26, 2020
ABSTRACT
Results of massive parallel sequencing-by-synthesis
vary depending on the sequencing approach.
CoolMPS™ is a new sequencing chemistry that incor-
porates bases by labeled antibodies. To evaluate the
performance, we sequenced 240 human non-coding
RNA samples (dementia patients and controls) with
and without CoolMPS. The Q30 value as indicator
of the per base sequencing quality increased from
91.8 to 94%. The higher quality was reached across
the whole read length. Likewise, the percentage of
reads mapping to the human genome increased
from 84.9 to 86.2%. For both technologies, we com-
puted similar distributions between different RNA
classes (miRNA, piRNA, tRNA, snoRNA and yRNA)
and within the classes. While standard sequencing-
by-synthesis allowed to recover more annotated miR-
NAs, CoolMPS yielded more novel miRNAs. The cor-
relation between the two methods was 0.97. Evaluat-
ing the diagnostic performance, we observed lower
minimal P-values for CoolMPS (adjusted P-value of
0.0006 versus 0.0004) and larger effect sizes (Co-
hen’s d of 0.878 versus 0.9). Validating 19 miRNAs re-
sulted in a correlation of 0.852 between CoolMPS and
reverse transcriptase-quantitative polymerase chain
reaction. Comparison to data generated with Illu-
mina technology confirmed a known shift in the over-
all RNA composition. With CoolMPS we evaluated
a novel sequencing-by-synthesis technology show-
ing high performance for the analysis of non-coding
RNAs.
INTRODUCTION
Since the mid 1990′s, massively parallel sequencing ap-
proaches have been developed and continuously improved.
The first commercial instruments were available on the mar-
ket around 2005 (1). The rapid development of technology
in the first 10 years had a substantial impact on genomic re-
search (2), also leading to a continuous growth of data de-
posited in resources such as GenBank (3). While one of the
most common applications is genome sequencing, RNAs
are often analyzed using high-throughput sequencing as
well. Even resolution at the single cell level can be reached
now (4). A general overview of the different sequencing ap-
proaches together with available instruments highlights the
diversity of available platforms and applications (5). Most
recently, a comparison of Illumina NextSeq 500, NovaSeq
6000 and the BGI MGISEQ-2000 using identical single Cell
3′ libraries generated with the 10× Genomics Chromium
platform highlighted comparable performance between the
platforms in general (6).
For the high-throughput analyses of small non-coding
RNAs (sncRNAs), sequencing has become one of the most
frequently used methods (7). This has led to a very deep
understanding of the sncRNA expression in humans (8,9)
and many other species (10). As a consequence, databases
on sncRNAs, especially on microRNAs (miRNAs) are up-
dated regularly with increasing numbers of miRNAs. The
miRBase in its most recent release 22 (October 2018 (11))
contains 38 589 entries from 271 species (12). Besides miR-
Base, MirGeneDB contains 10 899 curated miRNAs from
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45 different organisms (13) and miRCarta (14) has the
ambition to provide a collection of all expressed small
RNAs. With 11 000 annual publications on miRNAs, these
databases cover particular needs of researchers and provide
an important source of information for future miRNA an-
notations (15). The largest fraction of miRNAs from high-
throughput sequencing has been annotated for Homo sapi-
ens. For example, as of August 2020, the miRMaster web
service (16) has been applied in over 1300 studies. Sequenc-
ing data of more than 74 000 human sncRNA samples were
evaluated and 1.1 trillion reads (1.1 × 1012) have been pro-
cessed using miRMaster. Notably, only a fraction of all
available sncRNA sequencing data has been analyzed using
the miRMaster tool, e.g. since only one organism is consid-
ered. Thus, the total number of sncRNA sequencing data
sets exceeds the figures given above substantially. The gold
standard sncRNA analysis software miRDeep/miRDeep2
(17,18) for example has been cited almost 2000 times. Con-
stantly decreasing cost and broader availability of sequenc-
ing systems will lead to a continuously growing amount of
sncRNA datasets in the future.
Many studies, however, indicate a severe influence of
sample handling, library preparation and the sequenc-
ing technology on the read quantity, composition and
quality (19–22). The most commonly applied approach is
sequencing-by-synthesis using Illumina systems. These are
available in combination with different library preparation
approaches (19). We previously evaluated the performance
of sequencing-by-synthesis on Illumina systems to com-
binatorial probe-anchor synthesis (cPAS)-based BGISEQ-
500 sequencer (23). As compared to the Illumina system
we found a larger variety of sncRNAs in the cPAS data,
including twice as much yet unknown microRNAs at that
time. Both sequencing approaches however rely on similar
sequencing-by-synthesis principles, incorporating labeled
nucleotides during each sequencing cycle.
The continuous development of library preparation and
sequencing approaches is leading to novel commercially
available systems and assay formats. The availability of
a new experimental approach however immediately calls
questions with respect to the validity of its data and the
comparability. Especially for applications in biomarker de-
velopment a platform change may significantly affect the di-
agnostic or prognostic performance of tests. Consequently,
two questions come up whenever a new experimental ap-
proach is available: how does the performance change if
technical replicates are compared between platforms and
how does it affect biological results?
Recently, a fundamentally novel sequencing approach
called CoolMPS has been introduced and made commer-
cially available through MGI Tech Co., Ltd, Shenzhen,
China (details are provided in the ‘Materials and Methods’
section). While it still relies on the sequencing-by-synthesis
principle as other methods, no labeled nucleotides are in-
corporated. In order to measure a signal intensity repre-
sentative for the incorporated base at each cycle, four spe-
cific antibodies, one recognizing each of the four natural
bases (A, T, C, G) are used. The approach promises higher
data quality by avoiding incorporation and detection in-
terference of base-linked dyes and providing stronger sig-
nals by attaching multiple molecules of a dye per anti-
body. The CoolMPS approach for sequencing non-coding
RNAs is described in the ‘Materials and Methods’ section.
More details on the sequencing kits and basic biochemi-
cal principles of the methodology and its application are
available with the user manual of the commercial kits and
as preprint (https://doi.org/10.1101/2020.02.19.953307). It
is mandatory to evaluate such new technologies with re-
spect to common application scenarios. Discovering single
nucleotide variants or small insertions and deletions pose
different challenges as compared to, e.g. the quantification
of RNAs in an at least pseudo-quantitative manner. In this
study, we set to present the first detailed and direct perfor-
mance comparison between the novel antibody-based la-
beling approach in comparison to standard sequencing-by-
synthesis using labeled nucleotides for the quantification of
small non-coding RNAs.
MATERIALS AND METHODS
RNA sample preparation and quality control
RNA from 2.5 ml whole blood collected in PAXgene
tubes was isolated using the PAXgene Blood miRNA Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s recommendations. RNA concentration and integrity
were measured using Nanodrop 2000 spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA) and RNA
6000 Nano Kit for Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA, USA), respectively. RNA was
aliquoted and used for the four experimental approaches
CoolMPS, BGISEQ, Illumina and reverse transcriptase-
quantitative polymerase chain reaction (RT-qPCR) as de-
scribed below. The study was approved by the ethical com-
mittee of the Medical Faculty of the University of Tuebin-
gen (Nr. 90/2009BO2). A list of samples included in the
study is available as Supplementary Table S1.
CoolMPS™ on the DNBSEQ-G400RS
MiRNA libraries were prepared using the MGIEasy Small
RNA Library Prep Kit (MGI Technologies, Shenzhen,
China; product number 1000006383) with 800 ng total
RNA input according to the manufacturer’s recommenda-
tions. First, adapter sequences were ligated to the 3′ end
of the RNA, followed by ligation of barcoded RT primers.
Next, a universal adapter was ligated to the 5′ end. The
RNA was then transcribed into cDNA by HiScript II Re-
verse Transcriptase in the presence of RNAse inhibitor.
The primers used for the reverse transcription contained
barcodes that allowed the pooling of up to 24 samples
per sequencing library. Then cDNA libraries were ampli-
fied by 18-cycles of PCR reactions. Amplified PCR prod-
ucts were size selected using 6% TBE gel electrophoresis
and the band from 100 to 120 bp was then purified with
spin-X centrifuge tube filters followed by ethanol precip-
itation. The purified PCR products were quantified using
Qubit dsDNA HS Assay kit (Invitrogen, Cat No. Q32854).
Twelve purified PCR products were pooled with 84 fmol
each (total 1 pmol) and circularized using a specific oligo
sequence complementary to sequences in both the 3´ and
5´ adaptors provided in the MGIEasy Small RNA Li-
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After purification, the single strand circularized DNA li-
brary was quantified using Qubit ssDNA Assay Kit (In-
vitrogen, Cat No, Q10212). Subsequently, DNA nanoballs
(DNBs) were generated using rolling circle amplification
from 60 fmol of single stranded, circularized DNA li-
brary for 25 min. The DNB concentration was determined
using Qubit ssDNA Assay Kit. The DNBs (concentra-
tion in the range of 8–20 ng/l) were mixed with load-
ing buffer by manual pipetting and subsequently loaded
onto DNBSEQ-G400RS 4-lane flowcells (product num-
ber 1000016985) using the MGIDL-200H DNB loader as
described in the CoolMPSTM High-throughput Sequenc-
ing Set User Manual provided with the kit. Loaded flow
cells were sequenced on the DNBSEQ-G400RS instrument
using CoolMPSTM SE50 beta sequencing kits, now avail-
able as commercial products (product number 1000019478,
MGI Tech Co., Ltd, Shenzhen, China) following manu-
facturers recommendation. The MGI CoolMPSTM SE50
kits are the standard product for small RNA sequencing.
Sequencing was performed by selecting the smallRNA se-
quencing plan from the application menu on the DNBSEQ-
G400RS. Single end sequencing of 50 bp along with 10 bp
of barcode was performed. The basic difference between
CoolMPS and standard sequencing-by-synthesis, relying
on incorporation of labeled nucleotides, is the incorpora-
tion of unlabeled, reversibly terminated nucleotides. The
fluorescent signal to detect the incorporated bases is gen-
erated by using base-specific 3′ block-dependent fluores-
cently labeled antibodies. After each cycle, the bound an-
tibodies are removed and 3′ blocking moiety on the sugar
group of the nucleotide regenerates the natural nucleotides.
This procedure has the advantage not leaving a mark on
the base and making the current sequencing cycle inde-
pendent on the previous one. Base calling and generation
of FASTQ files on the DNBSEQ-G400RS was performed
using the software release for CoolMPS (BasecallLite ver-
sion 1.0.7.84). An important machine quality control step
included the removal of tiles from the FASTQ files that
failed at some point in the base calling process leading to
‘N’ bases for all reads in that respective tile. A detailed de-
scription of the CoolMPS method and procedures is avail-
able under: https://doi.org/10.1101/2020.02.19.953307. The
sequencing has been performed by Complete Genomics
Incorporated, San Jose, California. The overall process
of library preparation and sequencing on the DNBSEQ-
G400 is referred to as ‘CoolMPS’ through the whole
manuscript.
BGISEQ-500 sequencing using standard cPAS
As described above for CoolMPS, the MGIEasy Small
RNA Library Prep Kit (product number 1000006383) was
used to generate circularized DNA libraries with 800 ng to-
tal RNA input according to the manufacturer’s recommen-
dations. The library preparation and DNB preparation pro-
cedures are exactly the same as the one described in the pre-
vious section. DNBs were loaded onto the flow cell using the
BGIDL-50 DNB loader and single end 50 bp sequencing
was performed using the BGISEQ-500RS High-throughput
Sequencing Set SE50 on the BGISEQ-500RS instrument.
The sequencing has been carried out in the Human Genetics
Department at Saarland University, Germany. This process
is referred to as ‘BGISEQ’ through the whole manuscript.
Illumina library preparation and sequencing
Libraries were prepared according to the protocol of the
TruSeq Small RNA Sample Prep Kit (Illumina) with 200
ng of total RNA per sample as starting material as de-
scribed previously (24). In brief, the concentration of the
libraries was assessed using a Bioanalyzer with the DNA
1000 Chip. Before sequencing, libraries were pooled in equal
amounts of batches of six samples and clustered with a con-
centration of 9 pmol in one lane each of a single read flow
cell. Sequencing of 50 cycles was performed on a HiSeq
instrument (Illumina). Demultiplexing of raw sequencing
data and generation of FASTQ files was performed with
CASAVA v1.8.2.
RT-qPCR
RT-qPCR experiments are described in detail in the origi-
nal publication (25). In brief, the miScript PCR system was
used with custom miRNA PCR arrays (all reagents from
Qiagen, Hilden, Germany). The PCR arrays were designed
in 96-well plates to measure the expression of human miR-
NAs and RNU48 as well as RNU6 as endogenous con-
trols. The RT-qPCR experiments have been performed in
the Human Genetics Lab of Saarland University. Reverse
transcription was performed using 100 ng total RNA as in-
put using miScriptRT-II kit in 20 l total volume. PCR re-
actions with 1 ng cDNA input in a total volume of 20 l
were set up automatically using the miScript SYBR Green
PCR system in a Qiagility pipetting robot (Qiagen, Hilden,
Germany).
Bioinformatics
The pre-processing of the FASTQ files of CoolMPS,
BGISEQ and Illumina has been done using miRMaster 1.1
(16,26). MiRMaster is freely accessible at https://www.ccb.
uni-saarland.de/mirmaster/. Briefly, adapters at the 3′ end
were trimmed, while allowing an error of maximum one
base and requiring a minimum overlap with the read of 10
bases. Reads were quality trimmed when the average qual-
ity dropped below 20 in a window of four consecutive bases
to ensure a high quality of reads used for the downstream
processing. All reads shorter than 17 bases after trimming
were discarded from all further analyses. Read duplication
levels were computed with FASTQC 0.11.8. The error rate
per base was estimated by mapping the trimmed reads to the
human genome with bowtie, while allowing up to three mis-
matches (command line: bowtie -v3 -k 1 –best –fullref) and
counting the mismatched bases with Samtools stats (ver-
sion 1.9, (27)). To further ensure the best comparability,
BGISEQ and Illumina data were subsampled to match the
CoolMPS distribution that was originally sequenced to a
lower extent. In detail, all samples were subsampled to a
read depth of 10 Million reads. Reads were mapped to the
primary assembly of GRCh38.p10 using bowtie 1.2.2 (28),
while allowing no mismatches and discarding reads map-
ping to over 100 locations (command line: bowtie -v0 -m
100 –best –strata –fullref). Read RNA classes were deter-
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GENCODE v25 (30), piRBase 1 (31), miRBase v22.1 and
GtRNAdb 18.1 (32) with the following parameters: -F SAF
–O –M –R –f –fracOverlap 0.9, which required an overlap
of at least 90% of a read with the annotated region and al-
lowed multimapping reads and overlapping features. MiR-
Base v22.1 miRNAs were quantified using miRMaster with
up to one mismatch and a variability of two bases allowed
at the 5′ end and five bases at the 3′ end. Novel miRNA
candidates were predicted with miRMaster with a required
minimum expression of five reads in at least 75% of all de-
mentia or control samples. Since we expect numerous false
positive hits from the next generation sequencing data we
performed a quality control of the newly predicted candi-
dates and evaluated them using the NovoMiRank tool (33).
NovoMiRank was applied using the default parameters, i.e.
miRBase versions 1–7 were used as reference to identify the
most reliable candidates. All further downstream analyses
have been carried out in R 3.6.1 (https://www.R-project.
org/). To test whether miRNAs were normally distributed,
Shapiro–Wilk tests were computed per miRNA using the
shapiro.test function from the stats package. As hypothesis
test, parametric t-test and non-parametric Wilcoxon Mann-
Whitney (WMW) test were performed using the t.test and
wilcox.test functions from the stats package. Statistical tests
for group comparisons were carried out as two-tailed and
un-paired tests. All P-values were subjected to adjustment
for multiple testing by using the Benjamini–Hochberg ap-
proach through applying the p.adjust function from the
stats package. To estimate the effect sizes, the area un-
der the receiver characteristic curve (AUC value) and the
Cohen’s D effect size were computed using the R pROC
package (1.15.0, (34)) and the R effsize package (0.7.4).
Plots were generated with ggplot2 (3.1.0), cowplot (0.9.4),
complexHeatmap (2.5.3, (35)), ggridges (0.5.1) and vioplot
(0.3.5). To compute the most significant overlap between the
CoolMPS and BGISEQ technology in terms of dementia
biomarkers we employed the dynamic programming based
DynaVenn approach (36). DynaVenn is freely accessible at
https://www.ccb.uni-saarland.de/dynavenn. Functional cat-
egories were analyzed by miRNA set enrichment analysis
with default parameters using miEAA 2.0 (37,38) with a list
of the miRNAs sorted with respect to their effect sizes as in-
put (with separate adjustment of categories and Benjamini–
Hochberg adjustment procedure).
RESULTS
Study setup allowing to evaluate technical and biological as-
pects
Primary aim of the study was to compare the combinato-
rial probe-anchor synthesis (cPAS)-based data using label-
ing of nucleotides to the data generated by the new antibody
labeled-based approach on the more recent DNBSEQ-
400RS systems. In the context of this manuscript, the for-
mer approach is referred to as BGISEQ and the latter as
CoolMPS. Secondary aim was to compare the performance
and comparability of both approaches in terms of potential
liquid biopsy biomarker tests. We thus selected a study setup
that allows to address both aims (Figure 1A). We sequenced
240 individual blood samples on both sequencing systems.
The 240 samples include 179 controls and 38 patients with
dementia. This part of the cohort has been used to evalu-
ate the performance of both technologies to detect dementia
biomarkers. Furthermore, the 240 samples include 17 indi-
viduals and 6 technical replicates. The latter samples were
not used for the biomarker study but to assess the general
stability and reproducibility of the technologies. Further, we
compared the data to RT-qPCR measurements of a subset
of 19 miRNAs in 189 samples and also evaluated the per-
formance in comparison to data generated by Illumina se-
quencers. A full list of miRNAs and samples together with
the respective Delta CT values from the RT-qPCR valida-
tion is available in Supplementary Table S2. We first eval-
uated the general performance of CoolMPS for quantifica-
tion of RNA and then provide results of CoolMPS as liq-
uid biopsy biomarker for dementia. The cohort was com-
posed of participants with an average age of 67.3 years and
a standard deviation of 12.3 years (Figure 1B). Details on
the sequencing approaches and data analyses are given in
the ‘Materials and Methods’ section.
Key performance indicators reveal improved quality of
CoolMPS
First, we compared the Q30 values for the reads from the
two sequencing approaches (Figure 1C). The Q30 value pro-
vides the percentage of bases sequenced with a Phred score
of at least 30, corresponding to an error rate of 0.1%. The
median Q30 of the BGISEQ was 91.8% while the median
Q30 of CoolMPS jumped to 94%, representing a significant
improved performance of CoolMPS (P < 10−10). Intrigu-
ingly, we observed the higher per base sequencing accuracy
over the complete read length not observing any drop at the
beginning or at the end of the read. Moreover, CoolMPS
showed lower variability in sequencing performance over
the read in general as well as lower variability per base in
the read (Figure 1D). While the variation of valid reads
per sequencing run still varied for the CoolMPS technol-
ogy we observed a constantly higher fraction of reads map-
ping without mismatches to the human genome (84.9% for
BGISEQ and 86% for CoolMPS; Figure 1E). We also inves-
tigated the GC content of the generated libraries and found
a median of 51.10% for BGISEQ and a median of 50.72%
for CoolMPS in the unprocessed data, which dropped to a
median of 42.38 and 41.60% for BGISEQ and CoolMPS
after adapter and quality trimming, respectively (Supple-
mentary Figure S1A and B). The mean quality scores per
position varied between 33.95 and 36.35 for CoolMPS and
even increased slightly toward the end of the read. In con-
trast, the BGISEQ reads varied between 27.95 and 36.17
and reached their peak at position 26. Then, the quality
of BGISEQ reads decreased until position 50 (Supplemen-
tary Figure S1C and D). The mean quality scores for the
trimmed files, i.e. those that did not contain any adapters,
varied similarly, although the mean quality scores decreased
more for longer reads. The estimated error rate was for both
technologies similar with a median of 0.74% for BGISEQ
and 0.76% for CoolMPS (Supplementary Figure S1E). For
both, the raw sequencing files, and the trimmed ones, we ob-
served a close to identical GC content distribution. For both
technologies we observed two distinct peaks at 51 and 57%
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Figure 1. Study setup and quality control. (A) In the study we measured 240 individual blood samples using two fundamentally different sequencing
approaches and compare the data by bioinformatics approaches before we compute the concordance to RT-qPCR profiles. The 240 samples include one
part that has been used only for assessment of technical properties (6 and 17 samples in blue and gray) as well as a second part to evaluate performance
related to biomarker discovery (176 controls in green and 38 dementia cases in orange). (B) Distribution of the age of the individuals included in the study,
shown as violin plot. The black box spans the first to the third quartile and the white dot shows the median. (C) Distribution of the average Q30 value per
sample for the two technologies, shown as boxplot (left) and dotplot (right). Each sample is shown as one dot. The boxes span the first to the third quartile
with the horizontal line inside the box representing the median value. The whiskers show the minimum and maximum values or values up to 1.5 times
the interquartile range below or above the first or third quartile if outliers are present. (D) Q30 value over all samples per technology as function of the
position in the read. The smoothed curve is fitted by a generalized additive model using a cubic regression spline. The gray area represents the confidence
interval of the fit. (E) Distribution of the percentage of reads mapping to the human reference genome hg38 without mismatch per technology, shown as
boxplot (left) and dotplot (right). Each sample is shown as one dot. The boxes span the first to the third quartile with the horizontal line inside the box
representing the median value. The whiskers show the minimum and maximum values or values up to 1.5 times the interquartile range below or above
the first or third quartile if outliers are present. (F) Scatter plot of the average expression of all miRNAs in all samples for the two technologies. The blue
line is the regression line. The Pearson correlation is shown in the upper left part of the plot. MiRNAs with a fold change larger than two between both
technologies are highlighted. (G) Heat map of the clustered expression z-scores of miRNAs (rows) and technical replicates (columns). The color code for
the columns represents the technology. The dendrogram shows the hierarchical clustering of the samples with Euclidean distance and complete linkage.
(H) Distribution of all 12*11/2 = 66 pairwise Pearson correlation coefficients, shown as violin plot. The black box spans the first to the third quartile
and the white dot shows the median. (I) Correlation matrix of the expression values of all miRNAs for all technical replicates. The dendrogram shows
the hierarchical clustering of the samples with Euclidean distance and complete linkage. (J) Scatter plot of miRNAs for the best correlation between two
technical replicates. The dotted line represents the angle bisector. The Pearson correlation is shown in the upper left part of the plot. The points are colored
according to the point density in their neighborhood. (K) Scatter plot of miRNAs for the worst correlation between two technical replicates. The dotted
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read length in both libraries after trimming peaked at 22, as
we expected from a miRNA enriched library (Supplemen-
tary Figure S1H). We further evaluated the duplication lev-
els of the CoolMPS and BGISEQ libraries. In both cases,
the distributions were again nearly identical, showing most
duplication levels above 10 000 (Supplementary Figure S1I
and J). This is expected from miRNA libraries, as often a
small number of miRNAs account for most of the reads.
Finally, we checked the read base composition and found
similar patterns. The first 22 bases reveal the most overrep-
resented sequence (i.e. the sequence of hsa-miR-451a), fol-
lowed by the bases of the adapter sequence for the raw reads,
and by less sequence specific bases for the trimmed reads
(Supplementary Figure S1K and L). For most of the tested
relevant key performance indicators (e.g. Q30 and reads
mapping to the human genome) that allow to compare the
general sequencing performance, CoolMPS yielded an in-
creased performance compared to the classical BGISEQ ap-
proach.
Next, we evaluated and compared the reproducibility of
the two technologies. When comparing the mean expression
of all samples for CoolMPS to BGISEQ we obtained an ex-
tremely high correlation of 0.999 (Figure 1F). The scatter
plot highlights a set of seven miRNAs, which were mea-
sured with higher expression in the CoolMPS data as com-
pared to BGISEQ (miR-19a-3p, miR-30a-5p, miR-6131,
miR-451b, miR-378g, miR-195-5p and miR-23c). Next, we
considered only the six technical replicates per technology.
There, these miRNAs reveal the same pattern as for the
complete set of samples, thus excluding variance related
to the disease status of the participants as potential cause
(Supplementary Figure S2). Sequence and structure prop-
erties of these miRNAs are shown in Supplementary Table
S3. Neither the length, nor the base composition or sec-
ondary structures reveal a joint pattern, arguing against a
technological bias. We then asked whether we observe a
clustering according to the sequencing approach or whether
CoolMPS and BGISEQ samples mix. Indeed, hierarchical
clustering indicates that the samples do not cluster by tech-
nology (Figure 1G). The Pearson correlation between all
12 × 11 / 2 = 66 pair wise comparisons of technical repli-
cates varied between 0.952 and 0.990 with a median per-
formance of 0.973 (Figure 1H). The correlation matrix re-
vealed marginal differences in the correlation coefficients
between all the BGISEQ replicates (median 0.980) in com-
parison to the ones between the CoolMPS samples (median
0.964) (Figure 1I). Also, the correlation between the two
technologies with a coefficient of 0.973 was high. The differ-
ences in the correlation lead to a tendency of technologies to
cluster together, although CoolMPS Technical Replicate 2
clustered with BGISEQ Technical Replicates 2 and 6. Scat-
ter plots for the best (Figure 1J) and the worst correla-
tion (Figure 1K) demonstrate the generally very high repro-
ducibility between the technologies that is in the same range
as technical replicates within the technologies. Most impor-
tantly, we did not observe any significant change between
the RNAs profiled with BGISEQ compared to CoolMPS
after adjustment for multiple testing, both, for the WMW
and the t-test.
Having understood basic performance of the sequencing
technology as well as core aspects on technological repro-
ducibility we next evaluated the content of the different se-
quencing approaches with respect to quantitative and qual-
itative aspects.
Composition of different RNA classes is similar between
BGISEQ and CoolMPS
The first question related to small non-coding RNA se-
quencing data is the representation of different RNA
classes. Different sample- and library preparation protocols
lead to varying results. For example, size selection is ap-
plied to enrich-specific populations of sncRNAs. To min-
imize respective effects and to focus on the performance
of the sequencing technique, we used the same libraries
for sequencing and purified small non-coding RNAs by gel
electrophoresis (see ‘Materials and Methods’ section). This
protocol has been optimized to enrich for miRNAs, how-
ever, leaving also reads to evaluate other RNA classes. The
distribution to the different classes matched generally very
well between BGISEQ and CoolMPS (Figure 2A). Espe-
cially, we observed the intended enrichment for miRNAs.
For BGISEQ, 91.7% of all mappable reads matched to miR-
NAs, for CoolMPS we even reached a higher mapping of
92.7%. The second most abundant RNA class was the En-
sembl’s misc RNA category, containing among others yR-
NAs and signal recognition particle RNAs (SRP RNAs).
This category contains 5.1% of all BGISEQ and 4.5% of all
CoolMPS reads. All other categories were covered by less
than 1% of reads in both technologies. The scatter plot con-
trasting the log10 percentages for both technologies high-
lights the very reproducible distribution of reads to the dif-
ferent RNA classes (Figure 2B). Since the protocol was op-
timized to enrich for miRNAs and our results demonstrate
that this enrichment was successful, we focused on compar-
ing the performance for this class of sncRNAs.
CoolMPS yields more novel miRNA candidates
With respect to different technologies a bias in sncRNA-
seq data is known. Especially for specimen types such as
whole blood where already an enrichment of selected miR-
NAs exist, additional technological bias can further impair
the data analysis. In whole blood, miRNA expression is
not uniformly distributed but few miRNAs are significantly
higher expressed than others. Technology bias further over-
amplifies the respective miRNA reads. These circumstances
complicate the discovery of new miRNAs with the aim of
completing the repertoire of annotated miRNAs (8). We
thus evaluated and compared the distribution of reads to
different miRNAs using the two sequencing technologies
and asked how many novel miRNA candidates could be ob-
tained. As expected, we observed an uneven distribution,
which is however highly concordant between the technolo-
gies (Figure 3A). At the same time, we discovered 124 novel
miRNA candidates using BGISEQ while CoolMPS based
results highlight 134 novel miRNA candidates (Figure 3B
and Supplementary Figure S3A). These findings suggest a
higher sensitivity in terms of discovering low abundant yet
unknown miRNA molecules. Remarkably, a large fraction
of all new microRNA candidates, in total 88, have been de-
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Figure 2. Distribution to the different sncRNAs classes. (A) Donut plot comparing the distribution of all RNA classes and intergenic regions that were
covered by reads from CoolMPS and BGISEQ. (B) Scatter plot that shows the percentage of reads mapping to the RNA classes and intergenic regions for
BGISEQ (x-axis) and CoolMPS (y-axis) on a logarithmic scale.
miRNA candidates we scored them using NovoMiRank.
The score computed by NovoMiRank considers sequence
and structural features and describes the average distance
of the new candidates to a reference set, which is per default
miRBase v1-7. The median score obtained for the com-
mon candidates was 1.12, while the technology specific can-
didates obtained median scores of 1.05 for CoolMPS and
1.00 for BGISEQ. As highlighted by the distribution shown
in Supplementary Figure S3B, the score ranges are simi-
lar between the approaches and only few candidates (four
detected by both CoolMPS and BGISEQ, three CoolMPS
specific and one for BGISEQ specific) showed scores above
1.5. The score of 1.5 has been set since it is the maximum
score observed for miRBase v1-7 miRNAs i.e. the refer-
ence set of NovoMiRank. In summary, both technologies
do not reveal quantitative differences in the quality of re-
ported miRNAs but only in the quantity, with remarkable
advantages of CoolMPS.
In comparing the distribution of miRNAs annotated in
the miRBase we observe 76.7% of all BGISEQ reads map-
ping to the most abundant miRNA (miR-451a; Figure 3C).
Using CoolMPS, 78.5% of all reads matched to this miRNA
(Figure 3D). The second most abundant miRNA is repre-
sented by 9 and 8.4% of all reads, respectively (miR-92a-
3p). In sum, the top five miRNAs are covered by 93.8%
of all reads in the BGISEQ and by 92.6% of all reads in
the CoolMPS approach. A more detailed breakdown by ex-
cluding the most abundant miR-451a demonstrates that the
order of the 10 most abundant miRNAs matches perfectly
between the two technologies (Figure 3E and F). At the
same time, the data reinforces that especially for biospec-
imens with an uneven distribution of miRNA molecules,
deep sequencing with the least possible bias is required to
profile known and to discover new miRNAs.
Comparing biomarker profiles shows high reproducibility be-
tween the different approaches
One of the most important question in introducing new
technologies is not only whether general performance im-
proves but also whether previous biological results can be
reproduced. One core example are biomarker tests. Often,
biomarker sets change substantially when a new quantifi-
cation approach is introduced. This might be an expected
and even desired result, e.g. if a new technology genera-
tion with higher technical sensitivity is introduced. But if
a new technology has the main task to support transla-
tion of biomarkers to care by facilitating better integration
into clinical workflows or lower experimental costs, origi-
nal biomarker profiles should not be compromised. We thus
evaluated the diagnostic performance of miRNA biomark-
ers using BGISEQ and CoolMPS and used a liquid biopsy
dementia test as validation example. We sequenced cases
with dementia as well as controls with similar age distribu-
tion (Figure 1A and B). As performance criteria we con-
sidered the result of two commonly used hypothesis tests,
the t-test and the WMW test. Since not all miRNAs were
normally distributed according to the Shapiro Wilk test,
we here focus on the results of the WMW test and pro-
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Figure 3. Distribution to microRNAs. (A) Distribution of the read percentage of the 10 most abundant miRNAs in the CoolMPS and BGISEQ data,
shown as boxplot (left) and dotplot (right). Each sample is shown as one dot. The boxes span the first to the third quartile with the horizontal line inside
the box representing the median value. The whiskers show the minimum and maximum values or values up to 1.5 times the interquartile range below or
above the first or third quartile if outliers are present. (B) Number of novel microRNA candidates for both technologies. (C) Pie chart for the top five
miRNAs on the BGISEQ. (D) Pie chart for the top five miRNAs on the CoolMPS. (E) Pie chart for the top ten miRNAs on the BGISEQ after exclusion
of the most abundant miR-451a. (F) Pie chart for the top ten miRNAs using CoolMPS after exclusion of the most abundant miR-451a.
tary Table S4 and 5). Because of known challenges with P-
values and the controversial discussion on this topic (39),
we also computed effect sizes, namely Cohen’s D and the
area under the receiver characteristics curve AUC. Detailed
results for each miRNA and each of the different metrics
are provided for both BGISEQ (Supplementary Table S4)
and CoolMPS (Supplementary Table S5). In terms of AUC,
BGISEQ and CoolMPS showed an almost identical distri-
bution (Figure 4A). The scatter plot displays a very high
degree of reproducibility (Pearson correlation coefficient
of 0.905) between the two technologies considering the di-
agnostic performance (Figure 4B). As consequence, also
the volcano plots for the two technologies were very simi-
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Figure 4. Diagnostic performance on dementia patients. (A) Distribution of the AUC values to differentiate between dementia and controls obtained for
both technologies. An AUC of 0.5 means no dys-regulation. A deviation from 0.5 toward one means an upregulation and toward zero a downregulation
of the biomarkers. The distribution is shown as boxplot (left) and dotplot (right). Each miRNA is shown as one dot. The boxes span the first to the third
quartile with the horizontal line inside the box representing the median value. The whiskers show the minimum and maximum values or values up to 1.5
times the interquartile range below or above the first or third quartile if outliers are present. (B) Scatter plot of the AUC values to differentiate between
dementia and controls in CoolMPS (x-axis) versus BGISEQ (y-axis). The black horizontal and vertical line represent the AUC value of 0.5, respectively.
The Pearson correlation is shown in the upper left part of the plot. The points are colored according to the point density in their neighborhood. (C)
Volcano plot showing the log2 fold change on the x-axis and the FDR adjusted negative log10 of the Wilcoxon–Mann–Whitney (WMW) P-value on the
y-axis for BGISEQ. Orange dots are located above the horizontal line and are significant. Blue and green dots above the horizontal and on the left / right
of the vertical lines are significant and have a fold-change above 2. (D) Same volcano plot as in Figure 4C, but for CoolMPS. (E) Result of DynaVenn that
presents the negative log10 of the overlap between the two miRNA sets dependent on how many miRNAs are included. The peak of the curve represents
the most significant overlap. (F) Scatter plot of the log2 CoolMPS expression (x-axis) and the negative delta CT value for the 19 miRNAs included in the
validation study. The Pearson correlation coefficient is shown in the upper left part of the plot. (G) Scatter plot of the AUC values to differentiate between
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the results we speculated that also the ranks of biomark-
ers were consistent between the two technologies. For the
top-10 markers of BGISEQ and CoolMPS we thus com-
pared the ranks and absolute values (Table 1). First, we rec-
ognized that the top marker performed better in CoolMPS
as compared to BGISEQ in all metrics, the raw P-value,
the adjusted P-value, the Cohen’s D and the AUC. The ad-
justed P-values were for example 0.0006 in BGISEQ data
and 0.0004 in CoolMPS data. Second, we observed that
four miRNAs were among the top 10 markers in both tech-
nologies (miR-3200-3p, let-7e-5p, miR-15b-5p, miR-19b-
3p). For other markers we computed partially very differ-
ent ranks. One of the most extreme examples is miR-3335-
5p, which is ranked 9th most significant in CoolMPS and
117th in BGISEQ. Nonetheless, this miRNA was signif-
icant in both approaches. On the one hand we observed
a very high correlation, on the other hand, we also no-
ticed substantial differences in the ranks, most likely re-
lated to the close range of the P-values, challenging the
concept of fixed thresholds. To overcome the bias of se-
lecting fixed rank ranges, we developed the DynaVenn ap-
proach that computes the most significant overlap between
two biomarker sets containing technical or biological repli-
cates. DynaVenn computed the best overlap in selecting the
best 112 miRNAs from BGISEQ and the best 126 miRNAs
from CoolMPS, yielding an overlap of 94 miRNAs and a
P-value of 2 × 10−35 (Figure 4E). Thus, the two biomarker
sets show a highly significant overlap which might have re-
mained hidden if only the top 10 markers would have been
considered.
Illumina sequencing data shows differently biased but com-
parable measurements
In addition to BGISEQ we also compared the performance
of CoolMPS to standard Illumina sequencing for small
non-coding RNAs on a subset of 12 samples (24). As part
of our quality control we filter reads shorter than 17 nu-
cleotides. We thus compared the fraction of filtered reads for
the three technologies on the subset of samples sequenced
by the three technologies. For BGISEQ, 2.76% (SD of 0.56)
of reads, for CoolMPS 3.90% (SD of 0.54) of reads and for
Illumina 3.95% (SD of 3.24%) of reads were excluded. In
a first analysis step we evaluated the Q30 values obtained
by both approaches and found a median Q30 of 94.95%
for Illumina in comparison to 93.10% for CoolMPS (Sup-
plementary Figure S4A). The quality profile revealed Q30
values going up to a median of 99.43% for Illumina in
the first 20 positions, whereas a strong drop could be ob-
served afterwards, going down to a Q30 of 87.33% at po-
sition 50 (Supplementary Figure S4B). In comparison, the
CoolMPS quality remained more stable for the complete
read length with an average Q30 of 93.12% (SD: 1.79%)
and even showed an increased quality toward the end of the
reads. For the fraction of reads that can be used in further
analyses, i.e. the ones mapping to the human genome, we
observed for CoolMPS a median of 90.74%, while for Illu-
mina only 77.85% could be mapped (Supplementary Figure
S4C). In the next step, we inspected the expression similarity
of both technologies and found a general agreement of both
with a Pearson correlation of 0.873 (Supplementary Figure
S4D). Nevertheless, we could observe 52 miRNAs with ex-
pression values differing by fold changes above 10, show-
ing the technological specific biases (e.g. hsa-miR-486-5p
was expressed 76 times higher in the Illumina samples). In
addition, we confirmed that the samples of both technolo-
gies clustered separately according to their miRNA profiles
(Supplementary Figure S4E) and showed a much higher
intra-technology expression correlation (Pearson correla-
tion of 0.960 for CoolMPS on median, 0.955 for Illumina)
than between technologies (median Pearson correlation of
0.742) (Supplementary Figure S4F and G). We then asked
if the RNA class distribution between both technologies
show similar patterns. We found that the CoolMPS sam-
ples showed a higher diversity of RNA classes, whereas the
Illumina samples contained a higher percentage of reads
mapping to piRNAs (0.70 versus 0.17% in CoolMPS) and
miRNAs (97.76 versus 94.98% in CoolMPS) (Supplemen-
tary Figure S5). Next, we focused on the composition of
the detected miRNAs and found that of the top 10 most ex-
pressed miRNAs of both technologies, six overlapped. The
largest differences could be observed for hsa-miR-486-5p
and hsa-miR-451a, which are both the most expressed miR-
NAs in Illumina and CoolMPS and differ by a fold change
of 76 and 87, respectively (Supplementary Figure S6A). For
the Illumina samples, thus only 9.48% of the reads could
be mapped to other miRNAs and after excluding the top 5
miRNAs, only 3.15% of the reads mapped to others (Sup-
plementary Figure S6B). For the CoolMPS samples, we ob-
served slightly increased mapping rates to the top five miR-
NAs on this subset of samples, with 5.60% of the reads map-
ping to the other miRNAs (Supplementary Figure S6C).
Supplementary Figure S6D and E show a detailed break-
down of the top expressed miRNAs, after excluding the
most abundant one. We also found that some miRNAs that
were detected with low abundance in one technology (e.g.
hsa-miR-223-3p and hsa-miR-185-5p for Illumina and hsa-
miR-142-5p for CoolMPS) were among the 10 most ex-
pressed miRNAs in the other. This reinforces the necessity
of deep sequencing, especially for the Illumina libraries, to
quantify a larger range of miRNAs.
RT-qPCR data largely fit to the CoolMPS measurements
Finally, it is important to understand whether a third and
independent technology validates the biomarker profiles.
Since we previously already validated the BGISEQ ap-
proach using RT-qPCR (23) and demonstrate in the present
work that CoolMPS is concordant to BGISEQ we can
speculate that the RT-qPCR data would also match the
CoolMPS profiles. To evaluate this hypothesis, we com-
pared the expression values of 19 miRNAs that have been
measured for 189 samples from the present study by RT-
qPCR (25). Between the mean log2 CoolMPS expression
and the negative delta CT values computed from RT-qPCR
we observed a high correlation of 0.823 (Figure 4F). To val-
idate how well this translates into biomarker patterns we
again computed the difference between controls and demen-
tia patients (Figure 4G). In this comparison we observed
10 miRNAs that were upregulated in both technologies, 5
miRNAs that were downregulated in both technologies and
four miRNAs that were discordantly regulated between the
technologies. According to Fishers Exact test this corre-
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Table 1. For the top 10 most significant miRNAs with both technologies the rank in each technology is provided, followed by nominal and adjusted
P-value, the effect size (Cohen’s D) and AUC
miRNA Rank BGISEQ Rank CoolMPS WMW raw P-value WMW adj P-value Cohen’s D AUC
hsa-miR-3688-3p 1 16 2.89E-06 0.0006 − 0.88 0.26
hsa-miR-3200-3p 2 4 3.23E-06 0.0006 − 0.87 0.26
hsa-let-7d-5p 3 17 6.98E-06 0.0007 0.83 0.73
hsa-miR-589-5p 4 51 9.26E-06 0.0007 − 0.79 0.27
hsa-miR-550a-3-5p 5 NA 9.39E-06 0.0007 0.78 0.73
hsa-let-7e-5p 6 6 1.06E-05 0.0007 0.82 0.73
hsa-miR-193a-3p 7 69 1.21E-05 0.0007 − 0.76 0.27
hsa-miR-4448 8 55 2.21E-05 0.0010 0.57 0.72
hsa-miR-15b-5p 9 8 2.55E-05 0.0010 0.77 0.72
hsa-miR-19b-3p 10 1 2.64E-05 0.0010 − 0.77 0.28
hsa-miR-181c-5p 21 2 2.38E-06 0.0004 − 0.80 0.26
hsa-miR-185-5p 48 3 4.84E-06 0.0006 − 0.75 0.26
hsa-miR-5695 12 5 7.70E-06 0.0006 − 0.76 0.27
hsa-miR-363-3p 33 7 2.15E-05 0.0011 0.75 0.72
hsa-miR-335-5p 117 9 5.55E-05 0.0022 − 0.44 0.29
hsa-miR-30b-5p 83 10 5.83E-05 0.0022 − 0.72 0.29
Bold miRNAs are in the top 10 for both technologies.
BGISEQ and CoolMPS AD miRNAs are matching known
AD miRNAs and correlated to functional categories
As described in the previous sections, the miRNAs identi-
fied by the CoolMPS and BGISEQ approach have a sig-
nificant diagnostic potential from a statistical perspective.
We asked whether the signatures matched previously pub-
lished results and which functional categories are enriched.
To this end, we employed a miRNA set enrichment analy-
sis using miEAA (37,38). As input the miRNAs were sorted
with respect to their CoolMPS effect sizes. Downregulated
miRNAs were most significantly associated to the miEAA
disease category ‘Downregulated in Alzheimer’s Disease’
(raw and adjusted P-value of 2.3 × 10−5 and 6.88 × 10−4)
while upregulated miRNAs were most strongly correlated
to glioma (raw and adjusted P-value of 0.002 and 0.025,
respectively). With respect to Gene Ontology and pathway
databases we computed two significant categories. Upregu-
lated AD miRNAs were enriched in chromosome conden-
sation (raw and adjusted P-value of 3.3 × 10−6 and 0.018)
as well as response to magnesium ion (raw and adjusted P-
value of 1.3 × 10−5 and 0.036).
DISCUSSION
Whenever new technologies emerge in a field it is manda-
tory to test the fit to former technologies. The more disrup-
tive a technological change is, the more the results differ
from previous ones. An extreme example is the step from
microarrays to RNA sequencing for analyzing expression
profiles. If a novel technology aims to improve a previous
one in a rather evolutionary manner by adapting and im-
proving a specific step, the research results should gener-
ally be more aligned with previous findings. In biomedicine,
such improvements can aim at an improved translational
aspect of research in making workflows easier to use or
in reducing the cost of assays. With CoolMPS we eval-
uated such an evolutionary improvement. Still, the main
principle is sequencing-by-synthesis and also the detec-
tion and evaluation approach stay the same. The main
difference is in using labeled antibodies instead of in-
corporating labeled nucleotides. While theoretical advan-
tages of this approach, e.g. a potential re-use of the se-
quencing chemistry, are obvious we don’t expect disrup-
tive new findings. It is essential to benchmark CoolMPS
to related high-throughput approaches, in our case stan-
dard cPAS sequencing-by-synthesis and Illumina sequenc-
ing, but also to a gold standard technology, in our case
RT-qPCR. As primary comparison high-throughput tech-
nology we selected cPAS on the BGISEQ since we already
previously performed a detailed benchmarking to the Il-
lumina sequencing-by-synthesis approach, highlighting the
advantages and disadvantages of both approaches (23). As
biospecimens we intentionally selected whole blood. Not
only because whole blood samples can be used to screen
for minimally invasive biomarkers but also because of their
challenging characteristics. The repertoire of small non-
coding RNAs varies between different blood cell types and
sncRNAs have a very high dynamic range. In fact, this
means that few high abundant molecules are sequenced of-
ten whereas low abundant molecules are hardly observed.
In whole blood small non-coding RNA sequencing data
generated by Illumina sequencers, partially over 90% of the
reads belong to miR-486-5p. While this miRNA is certainly
highly abundant in red blood cells, this extreme distribu-
tion does not seem to match reality. In both, the BGISEQ
and CoolMPS data we still observe an extreme distribution
with around 34 of all reads matching to the most abundant
miRNA, miR-451a. This can also be recognized in Supple-
mentary Figure S1K and L. Still, this distribution is less
extreme than for the previously investigated Illumina se-
quencing data. The less extreme overrepresentation in the
BGISEQ and CoolMPS data thus facilitates the discov-
ery of yet unknown and less abundant non-coding RNA
molecules.
Among the top 10 markers that we discovered by
CoolMPS (Table 1), eight miRNAs (miR-19b-3p, miR-
181c-5p, miR-185-5p, miR-3200-3p, let-7e-5p, miR-15b-5p,
miR-335-5p and miR-30b-5p) were already described in the
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tia. For example, miR-19b-3p prevents amyloid -induced
injury by targeting BACE1 in SH-SY5Y cells (40) and is al-
tered in CSF exosomes of AD patients (41). Similarly, miR-
185-5p is known as exosomal AD biomarker (42). Also,
let-7e-5p and miR-3200-3p were previously identified as
blood biomarkers (43). Interestingly, the same manuscript
also lists miR-30c-5p, miR-30d-5p and miR-15a-5p. For
these miRNAs we report differential expression in related
miRNA family members (miR-30b-5p and miR15b-5p re-
spectively). The latter miRNA has also been reported in
other studies a circulating AD biomarker (44,45) and tar-
gets the amyloid precursor protein (46). Similarly, miR-335-
5p inhibits -Amyloid in AD (47). Already for the 10 most
significant miRNAs we thus found substantial evidence for
their role in AD, both as biomarker but also linked to a po-
tential pathogenic function.
One step in our analysis pipeline is to filter out short
reads (below 17 nucleotides), that might add noise to the
data. For BGISEQ, the lowest number of reads was fil-
tered out in this step followed by CoolMPS and lllumina
sequencing data. While the percentages overall were sim-
ilar, we observed a higher standard deviation in Illumina
data (3.24%) as compared to BGISEQ (0.54) and CoolMPS
(0.56) data. In comparing CoolMPS data to Illumina data
we observed a slightly better averaged Q30 value for the
Illumina data. This advantage could be observed however
mostly in the beginning of the read. Toward the end of the
50 base reads, Illumina Q30 values dropped more as com-
pared to the stable performance of CoolMPS. This resulted
in a higher mapping rate of the CoolMPS data. One expla-
nation for a drop of quality is in the small size of miRNAs
that are usually shorter than 25 nucleotides but 50 bases are
sequenced. This effect might be more pronounced for Illu-
mina as compared to the BGISEQ and CoolMPS data. In
consequence, we can expect that this factor is likely less rel-
evant for longer RNAs or sequencing of DNA. Also, the
composition of the RNA classes was different between the
technologies. Illumina data revealed higher percentages of
piRNAs and miRNAs while CoolMPS shows a higher di-
versity also including other non-coding RNA classes. A dif-
ference between the BGISEQ/CoolMPS and Illumina pro-
tocols was the amount of starting material. For BGISEQ
and CoolMPS, 800 ng was used while the Illumina data have
been generated from 200 ng input material. This might pre-
tend that a higher input amount is required for CoolMPS
as compared to Illumina. We used this higher input amount
however only during the exploratory phase of the CoolMPS
protocol. Even with lower amount of input material down
to 100ng we did not observe significant changes (data not
shown). Indeed, the manufacturer’s instruction would even
allow input from 10ng RNA only. Thus, the input volume
seems not to be a limiting factor for the CoolMPS technol-
ogy.
In sum, both of the technologies have their advantages
and disadvantages and the best systems should be cho-
sen dependent on the application. Our data thus clearly
suggest that small RNA sequencing results from Illumina
data should not be directly compared to sequencing results
from BGISEQ since the technical differences between iden-
tical samples are statistically highly significant. With respect
to comparing between BGISEQ and CoolMPS datasets
we observed generally very similar performance. The most
striking advantage of CoolMPS is a significantly improved
single base call quality. This led to marginal improvements
in the biomarker patterns but did not improve the perfor-
mance of any biomarker in a substantial manner. Interpret-
ing the results, we have to bear in mind that the BGISEQ
technology and chemistry have already matured over at
least five years while we used prototype beta testing chem-
istry for CoolMPS. Since already this chemistry lead to im-
proved performance we can expect further improvements
with revised kits of CoolMPS. Finally, one big advantage
is the potential to recover the used labeled antibodies for a
second sequencing run.
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